Xiaomin Wan

Dr. Xiaomin Wan


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
YPYe Peng
Ye Peng
XZXiaohui Zeng
Xiaohui Zeng
LPLiubao Peng
Liubao Peng
QLQiao Liu
Qiao Liu
LYLidan Yi
Lidan Yi
CTChongqing Tan
Chongqing Tan
Objective: The ORIENT-32 clinical trial revealed that sintilimab plus bevacizumab biosimilar significantly improved the median progression-free survival and median overall survival (OS) compared with sorafenib. This analysis evaluated the cost-effectiveness of sintilimab plus bevacizumab biosimilar as a first-line treatment for unresectable hepatocellular carcinoma from the Chinese perspective of healthcare system.Materials and methods: A Markov model with three mutual health states was constructed to evaluate the economic outcome of sintilimab plus bevacizumab biosimilar. The model cycle was 21 days, and the simulation time horizon was a lifetime. The output parameters of the model were the total cost, life-year (LY), quality-adjusted LY (QALY), and incremental cost-effectiveness ratio (ICER). Sensitivity analyses were conducted to assess the robustness of the results.Results: The base-case results found that sintilimab plus bevacizumab biosimilar provided an improvement of 1.27 QALYs and 1.84 LYs compared with sorafenib, and the ICER was $23,352/QALY. The hazard ratio for OS had the greatest influence on the ICER. The probability of sintilimab plus bevacizumab biosimilar was 85% at willingness-to-pay thresholds of $30,552/QALY.Conclusion: The findings of this analysis suggested that sintilimab plus bevacizumab biosimilar was a cost-effective first-line therapy for patients with unresectable hepatocellular carcinoma.

31 August 2022 in Journal of Endocrinological Investigation
Verified
Journal Article
Closed access
PDF file
CLC. Luo
C. Luo
SQS.-X. Qin
S.-X. Qin
QWQ.-Y. Wang
Q.-Y. Wang
YLY.-F. Li
Y.-F. Li
XQX.-L. Qu
X.-L. Qu
XWXiaomin Wan
Xiaomin Wan

28 May 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
SLSiNi Li
SiNi Li
JLJianHe Li
JianHe Li
LPLiuBao Peng
LiuBao Peng
YLYamin Li
Yamin Li
XWXiaomin Wan
Xiaomin Wan
Introduction: Recently, a phase III CROWN trial compared the efficacy of two anaplastic lymphoma kinase (ALK) inhibitors and demonstrated that lorlatinib displayed clinical improvement over crizotinib for advanced non-small cell lung cancer (NSCLC) patients. Therefore, the aim of this study was to estimate the cost-effectiveness of lorlatinib as a first-line therapy for patients with advanced ALK-positive (+) NSCLC. Materials and Methods: A cost-effectiveness analysis was performed using a microsimulation model from the US payer perspective and a lifetime horizon (30 years) in patients with previous untreated advanced ALK+ NSCLC. Based on the CROWN trial, patient characteristics were obtained, and the transition probabilities were estimated. All direct costs were derived from official sources and published literature. The main outcomes of the model were total costs, incremental cost-effectiveness ratio (ICER), quality-adjusted life years (QALYs), and life years (LYs). One-way and probabilistic sensitivity analyses and multiple scenario analyses were conducted to test the robustness of the model outcomes. Results: In the base case analysis, in which 1 million patients were simulated, treatment with lorlatinib or crizotinib as the first-line treatment was related to a mean cost of $909,758 and $616,230 (incremental cost: $293,528) and a mean survival of 4.81 QALYs and 4.09 QALYs (incremental QALY: 0.72) per patient, respectively. The main drivers of cost effectiveness were drug price and subsequent cost. PAS indicated that lorlatinib has 90% cost-effectiveness when compared to crizotinib when the willingness-to-pay (WTP) threshold in increased to $448,000/QALY. Scenario analysis demonstrated that lorlatinib has 100% cost-effectiveness at a WTP threshold of 200,000/QALY compared to crizotinib treatment when the price of lorlatinib is decreased to 75% ($424.5) of its original price. Conclusions: In this study, lorlatinib was unlikely to be cost effective compared with crizotinib for patients with previously untreated advanced ALK+ NSCLC at a WTP threshold of 200,000/QALY.

21 May 2021 in Advances in Therapy
Verified
Journal Article
Closed access
PDF file
SQShuxia Qin
Shuxia Qin
LYLidan Yi
Lidan Yi
SLSini Li
Sini Li
CTChongqing Tan
Chongqing Tan
XZXiaohui Zeng
Xiaohui Zeng
XWXiaomin Wan
Xiaomin Wan

9 September 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
ALAndong Li
Andong Li
MWMeiyu Wu
Meiyu Wu
OXOuyang Xie
Ouyang Xie
HXHeng Xiang
Heng Xiang
KMKehui Meng
Kehui Meng
XWXiaomin Wan
Xiaomin Wan
Background and objective: The EV-302 trial found that the combination of enfortumab vedotin (EV) with pembrolizumab significantly improved survival for patients with metastatic urothelial carcinoma (mUC). However, given the high cost of the drugs, there is a need to assess its value by considering both efficacy and cost. This study assessed the cost-effectiveness of EV plus pembrolizumab as a first-line treatment for patients with mUC from the perspective of U.S. payers.Methods: A Markov model was developed to compare the lifetime costs and effectiveness of EV in combination with pembrolizumab with chemotherapy in the treatment of mUC patients from U.S. payer perspective. Life-years (LYs), quality-adjusted LYs (QALYs), and lifetime costs were estimated. One-way, two-way and probabilistic sensitivity analyses were conducted to evaluate model uncertainty. Additionally, subgroup analyses were performed.Results: Compared to chemotherapy, the combination of EV and pembrolizumab provided an additional 2.10 LYs and 1.72 QALYs, at an incremental cost of $962,240.8 per patient. The incremental cost-effectiveness ratio (ICER) is $558,973 per QALY. Subgroup analysis indicated that patients ineligible for cisplatin treatment had a lower ICER compared to those who were eligible for cisplatin.Conclusions: From the perspective of US payers, at a willingness-to-pay threshold of $150,000 per QALY, the combination of EV and pembrolizumab is estimated to not be cost-effective compared to traditional chemotherapy in the first-line treatment of mUC patients.

7 June 2021 in Advances in Therapy
Verified
Journal Article
Closed access
PDF file
YPYe Peng
Ye Peng
XZXiaohui Zeng
Xiaohui Zeng
LPLiubao Peng
Liubao Peng
QLQiao Liu
Qiao Liu
LYLidan Yi
Lidan Yi
CTChongqing Tan
Chongqing Tan